Consequently, EGFR inhibition counteracted FOXQ1-dependent tumour growth, vascularisation, and metastasis in mouse xenograft assays, and this beneficial effect was further enhanced by co-treatment with the VEGF receptor inhibitor sunitinib [81]. Here, FOXQ1 is linked to neoplasm.